Patents by Inventor Jorge Eugenio Mora Alarcon

Jorge Eugenio Mora Alarcon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11873331
    Abstract: Monoclonal antibodies or fragments thereof are disclosed, which are binding to the protein P of the human Respiratory Syncytial Virus (RSV) which has a variable region of the heavy chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID 5 or a variable region of the light chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No:2 or SEQ ID No: 6. Also provided are diagnostic methods ex vivo or in vitro for detection of the viral antigen P of RSV, in which are used the monoclonal antibodies produced and secreted by the hybridomas 2E6/D2 and 6H5/H1. The invention can be used in detection for RSV kits, having the antibodies produced by the mentioned hybridomas.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: January 16, 2024
    Assignee: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
    Inventors: Susan Marcela Bueno Ramirez, Alexis Mikes Kalergis Parra, Jorge Eugenio Mora Alarcon
  • Publication number: 20210070844
    Abstract: Monoclonal antibodies or fragments thereof are disclosed, which are binding to the protein P of the human Respiratory Syncytial Virus (RSV) which has a variable region of the heavy chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID 5 or a variable region of the light chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No:2 or SEQ ID No: 6. Also provided are diagnostic methods ex vivo or in vitro for detection of the viral antigen P of RSV, in which are used the monoclonal antibodies produced and secreted by the hybridomas 2E6/D2 and 6H5/H1. The invention can be used in detection for RSV kits, having the antibodies produced by the mentioned hybridomas.
    Type: Application
    Filed: November 2, 2020
    Publication date: March 11, 2021
    Inventors: Susan Marcela BUENO RAMIREZ, Alexis Mikes Kalergis Parra, Jorge Eugenio Mora Alarcon
  • Patent number: 10858419
    Abstract: The present invention refers to monoclonal antibodies or fragments thereof which are binding to the protein P of the human Respiratory Syncytial Virus (RSV) which comprise a variable region of the heavy chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID 5 or a variable region of the light chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No:2 or SEQ ID No: 6. The invention provides also diagnostic methods ex vivo or in vitro for detection of the viral antigen P of RSV, in which are used the monoclonal antibodies produced and secreted by the hybridomas 2E6/D2 and 6H5/H1. The invention can be used in detection for RSV kits, comprising the antibodies produced by the mentioned hybridomas.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: December 8, 2020
    Assignee: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
    Inventors: Susan Marcela Bueno Ramirez, Alexis Mikes Kalergis Parra, Jorge Eugenio Mora Alarcon
  • Patent number: 10766948
    Abstract: The present invention refers to monoclonal antibodies, or fragments thereof, which recognize the pIII protein of the Adenovirus (ADV), useful for developing diagnostic methods of ADV infection in humans. Particularly, it refers to a monoclonal antibody or fragment thereof comprising a variable region of the heavy chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID No: 5 and a variable region of the light chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 2 or SEQ ID No: 6. It also is addressed to the nucleotide sequences which define said antibodies, in vitro and/or ex vivo diagnostic methods of ADV infection in a biological sample using said monoclonal antibodies, and diagnostic kits for detecting ADV comprising at least one monoclonal antibody against ADV according to the above description.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: September 8, 2020
    Assignee: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
    Inventors: Susan Marcela Bueno Ramirez, Alexis Mikes Kalergis Parra, Jorge Eugenio Mora Alarcon
  • Publication number: 20190048065
    Abstract: The present invention refers to monoclonal antibodies, or fragments thereof, which recognize the pIII protein of the Adenovirus (ADV), useful for developing diagnostic methods of ADV infection in humans. Particularly, it refers to a monoclonal antibody or fragment thereof comprising a variable region of the heavy chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID No: 5 and a variable region of the light chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 2 or SEQ ID No: 6. It also is addressed to the nucleotide sequences which define said antibodies, in vitro and/or ex vivo diagnostic methods of ADV infection in a biological sample using said monoclonal antibodies, and diagnostic kits for detecting ADV comprising at least one monoclonal antibody against ADV according to the above description.
    Type: Application
    Filed: January 20, 2017
    Publication date: February 14, 2019
    Applicant: Pontificia Universidad Catolica De Chile
    Inventors: Susan Marcela BUENO RAMÍREZ, Alexis Mikes KALERGIS PARRA, Jorge Eugenio MORA ALARCÓN
  • Publication number: 20180327483
    Abstract: The present invention refers to monoclonal antibodies or fragments thereof which are binding to the protein P of the human Respiratory Syncytial Virus (RSV) which comprise a variable region of the heavy chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID 5 or a variable region of the light chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No:2 or SEQ ID No: 6. The invention provides also diagnostic methods ex vivo or in vitro for detection of the viral antigen P of RSV, in which are used the monoclonal antibodies produced and secreted by the hybridomas 2E6/D2 and 6H5/H1. The invention can be used in detection for RSV kits, comprising the antibodies produced by the mentioned hybridomas.
    Type: Application
    Filed: July 25, 2016
    Publication date: November 15, 2018
    Inventors: Susan Marcela BUENO RAMIREZ, Alexis Mikes KALERGIS PARRA, Jorge Eugenio MORA ALARCON
  • Patent number: 9995747
    Abstract: The invention relates to murine monoclonal antibodies corresponding to monoclonal antibodies secreted by cell lines of hybridomas denominated 3G8/C11 and 7G4/A12, and which react against the antigen M of hMPV. Said antibodies do not compete with each other for the binding site for binding to the antigen, nor do they impede the simultaneous binding thereof to the antigen. Said monoclonal antibodies can be used for tests for the detection, diagnosis and/or determination of infection by hMPV.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: June 12, 2018
    Assignee: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
    Inventors: Susan Marcela Bueno Ramirez, Alexis Mikes Kalergis Parra, Jorge Eugenio Mora Alarcon
  • Publication number: 20170343546
    Abstract: The invention relates to murine monoclonal antibodies corresponding to monoclonal antibodies secreted by cell lines of hybridomas denominated 3G8/C11 and 7G4/A12, and which react against the antigen M of hMPV. Said antibodies do not compete with each other for the binding site for binding to the antigen, nor do they impede the simultaneous binding thereof to the antigen. Said monoclonal antibodies can be used for tests for the detection, diagnosis and/or determination of infection by hMPV.
    Type: Application
    Filed: February 2, 2015
    Publication date: November 30, 2017
    Inventors: Susan Marcela BUENO RAMIREZ, Alexis Mikes KALERGIS PARRA, Jorge Eugenio MORA ALARCON
  • Patent number: 9273122
    Abstract: The use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, to a monoclonal antibody IgG2A secreted by the cell line of 8A4/G9 hybridoma specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. The antibodies are in the pure state and do not contain any other contaminating biological material. A method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a given host is provided, including the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease. The antibody can be humanized in order to minimize the possibility of an immune response against the same in the patient.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: March 1, 2016
    Assignee: Pontificia Universidad Catolica de Chile
    Inventors: Alexis Mikes Kalergis Parra, Susan Marcela Bueno Ramirez, Jorge Eugenio Mora Alarcon, Roberto Sebastian Gomez Johnson
  • Publication number: 20140348858
    Abstract: The use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, to a monoclonal antibody IgG2A secreted by the cell line of 8A4/G9 hybridoma specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. The antibodies are in the pure state and do not contain any other contaminating biological material. A method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a given host is provided, including the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease. The antibody can be humanized in order to minimize the possibility of an immune response against the same in the patient.
    Type: Application
    Filed: November 23, 2012
    Publication date: November 27, 2014
    Inventors: Alexis Mikes Kalergis Parra, Susan Marcela Bueno Ramirez, Jorge Eugenio Mora Alarcon, Roberto Sebastian Gomez Johnson